Senior Medical Director, Clinical Development, Hepatology
GlaxoSmithKline
Pennsylvania, US
Base: $284,625 to $474,375 (us); bonus/equity: ann...
Hepatology clinical development
Steatotic liver disease (sld) focus
Clinical trial design and execution
Provide clinical and scientific leadership for potential new, established and emerging indications for assets in clinical development with a strong focus on steatotic liver disease (SLD), including alcohol-associated liver disease (ALD)
Job Summary
Provide clinical and scientific leadership for potential new, established and emerging indications for assets in clinical development with a strong focus on steatotic liver disease (SLD), including alcohol-associated liver disease (ALD).
Contribute to the clinical development strategy for a drug or program and ensure execution of clinical development plans (CDP) for product(s) and/or indication(s).
This career opportunity requires an on-site office presence (minimum of two days a week) at one of GSK’s US (PA or MA) or UK (Stevenage or London HQ) sites.
Matching Summary
Provide clinical and scientific leadership for potential new, established and emerging indications for assets in clinical development with a strong focus on steatotic liver disease (SLD), including alcohol-associated liver disease (ALD).
Salary
Base: $284,625 to $474,375 (US); Bonus/Equity: annual bonus and eligibility for long-term incentive program; Benefits: health care, insurance, retirement, paid time off
Skills & Requirements
Must-have
Hepatology clinical development
Steatotic Liver Disease (SLD) focus
Clinical trial design and execution
Medical monitoring oversight
Global regulatory interactions
Nice-to-have
Innovative methodologies and processes
Enterprise mindset
Strategic thinking and problem-solving
Navigating ambiguity
Key Requirements
Medical degree and clinical medical specialty training board qualification/registration
Experience in global pharmaceutical/biotechnology industry
Experience in Hepatology drug development
Experience in late-stage clinical trials (Phase 2 and Phase 3)